Biodesix飙升43%，预计财年收入将超过预期

2026-01-12 20:17

Precision diagnostics company Biodesix (BDSX) stock price climbed 41% on Monday during pre-market hours of trading as the company reported its preliminary Q4 and FY numbers, expecting a 24% jump to FY revenue, beating guidance of $84M-$86M.
Total Q4 revenue is expected to reach $28.8M, up 41% Y/Y. Analyst estimates at $25.02M.
FY 2025 revenue hit $88.5M, a 24% increase over last year, beating company guidance and analyst estimates of $84.74M.
Lung Diagnostics revenue is estimated to be $25.2M and $79.2M for Q4 and FY, respectively, an increase of 47% and 22% Y/Y.
Cash and cash equivalents stood at ~$19M as of December 31, 2025, including $2.3M from at-the-market offerings.

More on Biodesix